New findings from a clinical trial of the drug tagraxofusp confirm its efficacy against the rare blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN).
from Cancer Currents: An NCI Cancer Research Blog http://bit.ly/2HmtkxB
from Cancer Currents: An NCI Cancer Research Blog http://bit.ly/2HmtkxB